Therapies aimed at reducing the levels of a protein called HDAC3 may improve cognitive decline in…
Articles by Joana Fernandes, PhD
Wave Life Sciences will start two Phase 1b/2a clinical trials to investigate the safety and tolerability of its products…
Huntington’s patients who are taking Xenazine for the twitching condition known as chorea can switch without concern to the newly approved Austedo,…
Mutations of the MSH3 gene may be associated with the progression of Huntington’s disease, according to a British study. The…
Mitoconix Bio has secured $20 million in financing to continue developing MTC-1203Â as a treatment for mitochondrial impairment in…
Low levels of a protein called Pyk2 may be associated with the development of Huntington’s disease, according to a new…
WAVE Life Sciences’ products WVE-120101 (SNP-1) and WVE-120102 (SNP-2) will enter clinical trials in mid-2017 as part of the effort…
Disruption in the trafficking of molecules in and out of the cell’s nucleus may contribute to the pathology of Huntington’s…
Stealth BioTherapeutics has started a Phase 1/2 clinical trial to investigate the safety and effectiveness of SBT-20 in patients with…
Treatment with Vaccinex’s experimental antibody VX15 was seen to stop loss of brain volume and activity in patients with late…